Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double‐blind randomised parallel group placebo‐controlled trial
- 30 January 2003
- journal article
- clinical trial
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 18 (4) , 271-275
Abstract
Many atypical antipsychotics show antagonism at both serotonergic and dopaminergic neurones and show fewer extrapyramidal side effects (EPS). Nefazodone blocks postsynaptic 5HT2A receptors and weakly inhibits serotonin reuptake. This study aimed to elucidate the role of nefazodone in the treatment of antipsychotic‐induced EPS. The trial was a double‐blind, randomised, placebo‐controlled trial of patients requiring antipsychotic treatment with haloperidol 10 mg daily; from which a subgroup of patients who developed EPS were selected for the study. Patients were randomised to add‐on therapy with either placebo (n = 24) or nefazodone (n = 25) 100 mg bd. EPS were measured on days 0, 3 and 7 using the Simpson Angus, Barnes akathisia, abnormal involuntary movement and Chouinard scales. Nefazodone significantly reduced EPS as measured by both the Simpson Angus scale and CGI (p = 0.007 and 0.0247, respectively). Akathisia and tardive dyskinesia did not differ between the two groups (p = 0.601; p = 0.507, respectively). These results suggest the role of 5HT2 antagonism in the mechanism of action of atypical antipsychotics with respect to lowering rates of drug‐induced EPS. In addition, a therapeutic role for nefazodone is suggested in the treatment of antipsychotic‐induced EPS. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 14 references indexed in Scilit:
- Mirtazapine for Neuroleptic-Induced AkathisiaAmerican Journal of Psychiatry, 2001
- Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled studyInternational Clinical Psychopharmacology, 2001
- Managing Antipsychotic-Induced Acute and Chronic AkathisiaDrug Safety, 2000
- Depressive Signs and Symptoms in SchizophreniaArchives of General Psychiatry, 1998
- Drug Induced PsychosisThe British Journal of Psychiatry, 1996
- The serotonergic antidepressant nefazodone inhibits the serotonin transporter: In vivo and ex vivo studiesLife Sciences, 1995
- Adverse effects of antipsychotic drugsCurrent Opinion in Psychiatry, 1994
- INTERACTION BETWEEN DOPAMINERGIC AND SEROTONERGIC SYSTEMSClinical Neuropharmacology, 1992
- 5-HT2 Antagonist Ritanserin in Neuroleptic-Induced ParkinsonismClinical Neuropharmacology, 1990
- Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotonergic afferencesBrain Research, 1987